Overview
Niclosamide for Mild to Moderate COVID-19
Status:
Completed
Completed
Trial end date:
2021-08-19
2021-08-19
Target enrollment:
0
0
Participant gender:
All
All
Summary
This study will evaluate the antihelmintic drug, Niclosamide, as a potential treatment for mild to moderate coronavirus disease 2019 (COVID-19).Phase:
Phase 2Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Tufts Medical CenterTreatments:
Niclosamide
Criteria
Inclusion Criteria:- Positive SARS-CoV-2 test by PCR
- No requirement of oxygen supplementation
- Ability to take oral medication
Exclusion Criteria:
- Known allergic reactions to any components of Niclosamide medication
- Participation in another trial or use of any experimental treatment for COVID-19,
including chloroquine, hydroxychloroquine, remdesivir, and lopinavir/ritonavir
- Hospitalization or requirement of hospitalization at the time of enrollment